John G Ullman & Associates Inc. Trims Stock Holdings in Eli Lilly and Company (NYSE:LLY)

John G Ullman & Associates Inc. lowered its holdings in Eli Lilly and Company (NYSE:LLY) by 11.0% in the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 3,558 shares of the company’s stock after selling 440 shares during the period. John G Ullman & Associates Inc.’s holdings in Eli Lilly and Company were worth $2,768,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of LLY. Resources Management Corp CT ADV raised its position in shares of Eli Lilly and Company by 15.1% during the 3rd quarter. Resources Management Corp CT ADV now owns 1,336 shares of the company’s stock worth $718,000 after purchasing an additional 175 shares during the period. Silver Oak Securities Incorporated raised its position in shares of Eli Lilly and Company by 7.9% during the 3rd quarter. Silver Oak Securities Incorporated now owns 1,684 shares of the company’s stock worth $905,000 after purchasing an additional 123 shares during the period. Tompkins Financial Corp raised its position in shares of Eli Lilly and Company by 3.5% during the 3rd quarter. Tompkins Financial Corp now owns 34,787 shares of the company’s stock worth $18,685,000 after purchasing an additional 1,163 shares during the period. Brown Shipley& Co Ltd raised its position in shares of Eli Lilly and Company by 11.1% during the 3rd quarter. Brown Shipley& Co Ltd now owns 10,881 shares of the company’s stock worth $5,845,000 after purchasing an additional 1,091 shares during the period. Finally, Comerica Bank acquired a new stake in shares of Eli Lilly and Company during the 3rd quarter worth approximately $345,781,000. Institutional investors own 82.53% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on LLY shares. Cantor Fitzgerald reiterated an “overweight” rating and set a $885.00 price target on shares of Eli Lilly and Company in a research report on Monday, July 1st. Truist Financial restated a “buy” rating and issued a $1,000.00 target price (up from $892.00) on shares of Eli Lilly and Company in a research report on Tuesday, June 25th. BMO Capital Markets restated an “outperform” rating and issued a $1,001.00 target price on shares of Eli Lilly and Company in a research report on Wednesday, July 3rd. Jefferies Financial Group raised their target price on Eli Lilly and Company from $994.00 to $1,015.00 and gave the company a “buy” rating in a research report on Monday, June 24th. Finally, Morgan Stanley restated an “overweight” rating and issued a $1,023.00 target price on shares of Eli Lilly and Company in a research report on Friday, July 5th. Three analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $843.00.

Eli Lilly and Company Price Performance

NYSE LLY traded down $5.59 on Thursday, reaching $934.19. 2,855,062 shares of the stock traded hands, compared to its average volume of 2,936,500. The company has a market cap of $887.86 billion, a price-to-earnings ratio of 137.58, a P/E/G ratio of 2.00 and a beta of 0.41. The company has a quick ratio of 1.03, a current ratio of 1.35 and a debt-to-equity ratio of 1.90. The firm’s fifty day simple moving average is $845.17 and its 200 day simple moving average is $760.02. Eli Lilly and Company has a 12 month low of $434.34 and a 12 month high of $945.69.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Monday, May 6th. The company reported $2.58 earnings per share for the quarter, topping the consensus estimate of $2.53 by $0.05. The business had revenue of $8.77 billion during the quarter, compared to analyst estimates of $8.94 billion. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The company’s revenue was up 26.0% compared to the same quarter last year. During the same period last year, the company posted $1.62 EPS. As a group, research analysts predict that Eli Lilly and Company will post 13.76 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Thursday, August 15th will be paid a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 0.56%. The ex-dividend date of this dividend is Thursday, August 15th. Eli Lilly and Company’s dividend payout ratio is presently 76.58%.

Insider Transactions at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 210,000 shares of the firm’s stock in a transaction on Wednesday, July 10th. The stock was sold at an average price of $939.82, for a total transaction of $197,362,200.00. Following the completion of the sale, the insider now directly owns 96,943,810 shares of the company’s stock, valued at approximately $91,109,731,514.20. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, major shareholder Lilly Endowment Inc sold 210,000 shares of the firm’s stock in a transaction on Wednesday, July 10th. The stock was sold at an average price of $939.82, for a total value of $197,362,200.00. Following the completion of the sale, the insider now owns 96,943,810 shares of the company’s stock, valued at $91,109,731,514.20. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CAO Donald A. Zakrowski sold 750 shares of the firm’s stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $819.47, for a total value of $614,602.50. Following the completion of the sale, the chief accounting officer now directly owns 7,130 shares of the company’s stock, valued at approximately $5,842,821.10. The disclosure for this sale can be found here. Insiders sold a total of 1,214,704 shares of company stock valued at $1,066,841,316 in the last three months. 0.13% of the stock is currently owned by corporate insiders.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.